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Abstract
Background: Several studies have investigated the association between non-statin lipid-lowering therapy and
regression of atherosclerosis. However, these studies were mostly small and their results were not always robust.
The objectives were: (1) to define if a dual lipid-lowering therapy (statin + non-statin drugs) is associated with
coronary atherosclerosis regression, estimated by intravascular ultrasound (IVUS); (2) to assess the association
between dual lipid-lowering-induced changes in low density lipoprotein cholesterol (LDL-C) and non-high-density-
lipoprotein cholesterol (non-HDL-C) levels and atherosclerosis regression.
Methods: A meta-analysis including trials of non-statin lipid-lowering therapy, reporting LDL-C, non-HDL-C and
total atheroma volume (TAV) with a minimum of 6 months of follow-up was performed. The primary endpoint was
defined as the change in TAV measured from baseline to follow-up, comparing groups of subjects on statins alone
versus combination of statin and non-statin drugs. The random-effects model and meta-regression were performed.
Results: Eight eligible trials of non-statin lipid-lowering drugs (1759 patients) were included. Overall, the dual lipid-
lowering therapy was associated with a significant reduction in TAV [− 4.0 mm3 (CI 95% -5.4 to − 2.6)]; I2 = 0%]. The
findings were similar in the stratified analysis according to the lipid-lowering drug class (ezetimibe or PCSK9
inhibitors). In the meta-regression, a 10% decrease in LDL-C or non-HDL-C levels, was associated, respectively, with
1.0 mm3 and 1.1 mm3 regressions in TAV.
Conclusion: These data suggests the addition of ezetimibe or PCSK9 inhibitors to statin therapy results in a
significant regression of TAV.
Reduction of coronary atherosclerosis observed with non-statin lipid-lowering therapy is associated to the degree of
LDL-C and non-HDL-C lowering. Therefore, it seems reasonable to achieve lipid goals according to cardiovascular
risk and regardless of the lipid-lowering strategy used (statin monotherapy or dual treatment).
Keywords: Intravascular ultrasound, Coronary atherosclerosis plaque, Ezetimibe, PCSK9 inhibitors, Non-statin
therapy, Atherosclerosis regression, Meta-analysis
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Introduction
Coronary plaque regression has a significant positive
correlation with low density lipoprotein cholesterol
(LDL-C) and non-high-density-lipoprotein cholesterol
(non-HDL-C) reduction [1]. Multiple diagnostic
methods have been used to assess the composition of
atherosclerotic plaque. Coronary intravascular ultra-
sound (IVUS) has been used in most of the studies that
evaluate the impact of pharmacological interventions on
the progression/regression of atherosclerosis. On the
other hand, the regression of atherosclerosis measure by
IVUS has been a subrogated endpoint of clinical cardio-
vascular events [2, 3].
The use of statins has been and continues today to be
the cornerstone of risk management of cardiovascular
disease. The robust evidence showing a reduction of car-
diovascular events has made statins essential in a variety
of clinical conditions with elevated cardiovascular risk
[4–6]. In the same way, several studies have demon-
strated that statin therapy promotes coronary atheroma
stabilization and regression in patients with acute coron-
ary events or stable coronary disease [7–11].
Despite reductions in LDL-C with statins, many people
still experience cardiovascular events (cardiovascular re-
sidual risk). Dual lipid-lowering therapy with ezetimibe
or inhibitors of proprotein convertase subtilisin kexin
type 9 (PCSK9) has been shown to be more effective
than statin monotherapy in high-risk patients with cor-
onary artery disease [12, 13]. In recent years, many stud-
ies have investigated the reduction of LDL-C with non-
statin drugs and Its impact on atherosclerosis regression.
However, the studies were mostly small and their results
were not always robust [14–21]. A previously published
meta-analysis showed an association between the regres-
sion of atheroma volume with the addition of ezetimibe
[22]. Nevertheless, this study did not include a meta-
regression to assess the relationship between the de-
crease in lipid markers achieved with dual lipid-lowering
therapy and plaque regression. Moreover, it didn’t evalu-
ate non-statin drugs such as PCSK9 inhibitors. The dual
therapy would be successful if it reduces an adequate
percentage in lipid levels and, consequently, attains re-
gression in the volume of atherosclerotic plaque. The
hypothesis of this investigation was that an additional
decrease in cholesterol levels with a non-statin therapy
would result in atherosclerosis regression, being greater
with more intensive decrease in lipid levels. Therefore,
the objectives of the present meta-analysis were: (1) to
define if a more aggressive dual lipid-lowering therapy
with non-statin drugs is associated with a regression in
coronary atherosclerosis estimated by IVUS; (2) to assess
the association between dual lipid-lowering-induced
changes in LDL-C and non-HDL-C levels and regression
of atherosclerosis.
Material and methods
Data extraction and quality assessment
This meta-analysis was performed according to the Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines for reporting sys-
tematic reviews [23]. A literature search was performed
that identified clinical trials of non-statin drugs that are
recommended by the current cholesterol guidelines
based on the results of clinical trials that showed efficacy
in the reduction of cardiovascular events, and published
between January 1990 and January 2020 in English. Two
independent reviewers searched the electronic PubMed/
MEDLINE, Embase and Cochrane Controlled Trials da-
tabases using the following terms: “endovascular ultra-
sound”, “IVUS”, “atherosclerosis regression”, “lipid-
lowering therapy”, “ezetimibe” and “PCSK9 inhibitors”.
All the analyzed studies meet the following inclusion
criteria: a) Comparisons of efficacy for a statin mono-
therapy versus statin plus non-statin therapy (ezetimibe
or PCSK9 inhibitor therapy); b) Follow-up duration ≥6
months; c) IVUS used as modality for measuring
changes in atheroma volume; c) Reporting of change in
atheroma between baseline and follow-up, expressed as
mean delta total atheroma volume (TAV); d) Reporting
the change in lipids values between baseline and follow-
up.
The primary endpoint of the study was defined as the
change in TAV measured from baseline to follow-up,
comparing groups of subjects on statins alone versus
combination of statin and non-statin drugs.
The dual therapy was used to investigate whether the
additional decrease in LDL-C or non-HDL-C was associ-
ated with a regression in the volume of atheroma in the
evaluated studies. Basal population risk is the main criter-
ion by which treatment without statins should be consid-
ered;in that sense, all selected studies included high or
very high cardiovascular risk patients. Only 3 studies eval-
uated in this meta-analysis determined as an inclusion cri-
teria having a baseline level of LDL-C > 100mg/dl.
When the summary/dispersion measures used to re-
port the difference in TAV between the arms were not
mean and standard deviation, conversion tools previ-
ously suggested by the literature were used [24].
Potential risks of bias were evaluated, using the
Cochrane tool developed for this purpose [25]. This tool
assesses bias in different domains: random sequence
generation (selection bias); allocation concealment (se-
lection bias); blinding of participants and study staff
(performance bias); blinding of outcome assessors (de-
tection bias); incomplete results data (attrition bias); se-
lective reporting of results (reporting bias); and other
sources of bias. Each domain was rated as “High”, “Low”
or “Unclear” depending on the judgment of each author
following the recommendations.
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Meta-analysis and meta-regression analyses
The summary effect of non-statin lipid- lowering drugs
on the TAV was estimated. Exploratory meta-regression
analyses were performed to examine the potential asso-
ciations between C-LDL and non-HDL-C reduction and
the effect sizes of non-statin lipid-lowering drugs on ath-
eroma regression.
Statistical analysis
Measures of effect size were expressed as mean differ-
ence, and the I2 statistic was calculated to quantify
between-trial heterogeneity and inconsistency. Because
studies differ in their lipid-modifying regimens and effect
sizes, a random-effects model was chosen. However, to
assess the relationship between differences in LDL-C
and non-HDL-C reduction and variations in mean dif-
ference of atheroma volume, a mixed-effects meta-
regression model was performed. To compare mean ef-
fects between subgroups, a Z test was used. The level of
statistical significance was set at a two-tailed alpha of
0.05. Statistical analyses were performed using the R
software for statistical computing version 3.5.1 with add-
itional specific packages [26].
Sensitivity analyses
Through this analysis, the results of the meta-analysis
were replicated excluding in each step one of the studies
included in the review. The analysis was considered ro-
bust when the results obtained were similar.
Analysis of publication bias: A funnel plot using the
standard error (SE) for mean difference was created, and
Begg and Mazumdar rank correlation were also per-
formed. In addition, Egger’s regression intercept tests
were done.
Results
Eight eligible trials of non-statin lipid-lowering drugs, in-
cluding 1759 patients, were identified and considered
eligible for the analyses. There was a total of 879 sub-
jects allocated to receive dual lipid-lowering therapy
Fig. 1 Flow diagram of the study screening process. TAV: total ateroma volumen; IVUS: intravascular ultrasound
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(statin plus ezetimibe or PCSK9 inhibitors) and 880 sub-
jects allocated to the respective control arms (statin
monotherapy). A flow diagram of the study’s screening
process has been shown in Fig. 1.
Seven studies were randomized and all of the trials
evaluated had a control arm. The quality of the studies
evaluated can be seen in Fig. 2.
Three studies included patients with chronic coronary
heart disease (HEAVEN, Masuda et al., GLAGOV) and
other four studies evaluated subjects after an acute cor-
onary syndrome (OCTIVUS, ZEUS, Hibi et al.,
ODYSSEY-J). The additional study accepted both op-
tions as inclusion criteria (PRECISE-IVUS). Six studies
that evaluated the addition of ezetimibe and two studies
that analyzed the additional effect of PCSK9 inhibitors
were included. In studies that included patients with
acute coronary syndrome, the IVUS measurement was
performed in a different coronary segment than the cul-
prit lesion.
The follow-up ranged between 6 and 19 months. The
characteristics of the studies included in the analysis can
be seen in Table 1.
Overall, this meta-analysis showed that dual lipid-
lowering therapy was associated with a significant reduc-
tion in TAV [− 4.0mm3 (CI 95% -5.4 to − 2.6)]; P <
0.0001; I2 = 0%] Fig. 3.
In the stratified analysis according to the lipid-
lowering drug class, the findings were similar: (1) ezeti-
mibe group: [− 4.0 mm3 (CI 95% -6.5 to − 1.5)]; P =
0.0018; I2 = 18%]; (2) PCSK9 inhibitor group: [− 3.9 mm3
(CI 95% -6.0 to − 1.7)]; P < 0.0001; I2 = 0%] Fig. 3.
In the meta-regression, the LDL-C reduction associ-
ated with dual lipid-lowering therapy was associated
with a significant reduction in TAV (P = 0.0083).
Fig. 2 a Individual bias assessment of included studies. b Summary bias assessment of included studies
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Fig. 3 Effect of non-statin lipid-lowering therapy on total atheroma volume. Global and subgroup drug analysis. Random effects, mean difference,
95% confidence intervals (CI) and I2 statistics. TAV: total atheroma volume; Dif: difference
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Furthermore, when we analyzed the non-HDL-C, meta-
regression showed similar results (P = 0.0057). In
addition, a 10% decrease in LDL-C or non-HDL-C levels,
was associated, respectively, with 1.0 mm3 and 1.1 mm3
regressions in TAV. Figures 4 and 5 show meta-
regression analysis by lipids values reductions.
The funnel plot of standard error by mean difference
of endpoints did not suggest publication bias Figure 6.
In the same way, Begg and Mazumdar’s test for rank
correlation gave a P value of 0.8046, not indicating pos-
sible publication bias. In addition, Egger’s regression
intercept tests gave a P value of 0.6876.
The sensitivity analysis showed that the results were
robust Fig. 7..
Discussion
In this meta-analyses, dual lipid-lowering treatment (sta-
tin plus ezetimibe or PCSK9 inhibitors) compared with
statin monotherapy was associated with greater reduc-
tion in TAV. The results were consistent in the global
and lipid-lowering drugs subgroups analysis, suggesting
that the decrease in LDL-C itself would be more relevant
than the pharmacological mechanism that generates it.
There is strong evidence of the relationship between
LDL-C levels, the regression of atherosclerotic plaque
and the reduction of cardiovascular events [1, 5]. Statins
play a role in plaque regression with reduction in lipid
content. These medications stabilize atherosclerotic
plaque with thickened fibrous layers and macrocalcifica-
tion [8].
Ezetimibe, an inhibitor of the Niemann-Pick C1-like 1
cholesterol transporter, is a relatively new drug for LDL-
C-lowering therapy [27]. Combination therapy with a
statin and ezetimibe produced better clinical outcomes
than statin monotherapy in the IMPROVE-IT study
[12]. Similarly, PCSK9 inhibitors are new pharmacologic
agents that have an incremental effect on lowering LDL-
C in statin-treated patients, combined with an excellent
safety profile [28]. In the recent FOURIER and ODYS-
SEY OUTCOMES trials, PCSK9 inhibition produced a
relevant reduction in serum LDL-C levels by suppressing
LDL-C receptor degradation and, consequently, has
demonstrated clinical efficacy, in addition to statin ther-
apy, in reducing cardiovascular events in patients with
clinical evident atherosclerotic disease [13, 29].
The effect of lipid reduction on the atheroma plaque
regression was mainly evaluated in statin trials. For ex-
ample, one of the pioneering investigations, the REVER-
SAL study, showed regression of the statin-mediated
coronary plaque when the decrease in LDL-C level
exceeded 50% [30].
The role of ezetimibe in atherosclerosis regression was
initially uncertain. The ENHANCE study did not find
significant changes in the intima-media thickness in pa-
tients with familiar hypercholesterolemia treated by sim-
vastatin with and without ezetimibe [31]. Nevertheless,
beyond some methodological limitations of this study,
the use of carotid ultrasound to assess the regression of
atherosclerosis has been displaced by IVUS. A recent
meta-analysis found no significant association between
LDL-C reduction and progression of atherosclerosis esti-
mated by carotid intima-media thickness [32].
Atherosclerotic plaque regression and conversion to a
stable phenotype is possible with intensive statin therapy
and can be demonstrated in patients using a variety of
non-invasive and invasive imaging modalities [33]. The
use of IVUS in the present analysis to evaluate atheroma
volume is a globally established method to evaluate the
vascular effect of lipid-lowering therapy. Previously, Mir-
zaee et al. showed that the addition of ezetimibe to statin
Fig. 4 Random-effects meta-regression analyses: Association between the difference in percentage LDL-C reduction among treatment arms and
treatment effect (total atheroma volume regression)
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therapy is effective in reducing total atheroma volume
assessed by IVUS [22]. However, they did not evaluate
other non-statin drugs such as PCSK9 inhibitors. Experi-
mental studies have suggested that PCSK9 might directly
promote inflammatory processes contributing to athero-
sclerosis [34]. Likewise, although it is widely accepted
that the association between PCSK9 and atherosclerosis
is dependent on PCSK9-mediated modulation of LDL
metabolism, there is a lot of evidence suggesting that
PCSK9 may also exert direct cholesterol-independent
pro-atherosclerotic effects [35]. However, a recent meta-
analysis failed to demonstrate an effect of PCSK9 inhibi-
tors on high sensitivity C-reactive protein concentra-
tions. This led to questioning the impact of these drugs
on systemic inflammation [36]. Two recent trials have
evaluated the effect of monoclonal antibodies on athero-
sclerosis regression. The GLAGOV trial reported the ef-
fectiveness of the PCSK9 inhibitor (evolocumab)
compared with statin alone, on plaque regression at the
LDL-C level of 36 mg/dL, further confirming “the lower
the better” theory [20]. The ODYSSEY J-IVUS trials
showed that alirocumab treatment over 36 weeks
Fig. 5 Random-effects meta-regression analyses: Association between the difference in percentage non-HDL-C reduction among treatment arms
and treatment effect (total atheroma volume regression)
Fig. 6 Funnel plot to assess publication bias
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resulted in a numerically greater but not statistically sig-
nificant percentage reduction in TAV [21]. The lack of a
statistically significant difference in the primary efficacy
endpoint observed in this study needs to be considered
in light of several specific factors of the study design,
such as the limited sample size and the short duration of
treatment period.
Consequently, it is essential to strengthen the evidence
on these new medications. The addition of a PCSK9 in-
hibitor to a statin regimen has been shown to further re-
duce LDL-C levels by 43 to 64% [37], and its use could
increase considerably since in usual clinical practice,
many patients do not reach the goals proposed by com-
bining statins with ezetimibe [38]. Likewise, the latest
published guidelines have recommended the use of eze-
timibe and PCSK9 inhibitors as additional medications
to reduce the residual risk of patients at higher risk [39,
40]. Therefore, we consider the evaluation of the impact
of both drugs on the regression of atherosclerosis as a
very important fact.
This is the first meta-analysis to demonstrate that the
combination of statin and ezetimibe or PCSK9 inhibitors
therapy is associated with a significantly greater reduc-
tion in TAV, compared with statin monotherapy.
Another point of this study is that it evaluates through
a meta-regression analysis the effect of lipid levels reduc-
tion generated by dual lipid-lowering therapy on the re-
gression of atherosclerosis.
A large body of evidence supports a central role for
LDL-C lowering in the prevention of atherosclerotic car-
diovascular disease [41]. It is proven that the process of
atherosclerosis strongly depends on LDL-C, but whether
or not this dependence is similar in statin regimens and
dual therapy regimens is less defined [17, 18]. It is there-
fore reasonable to think that the effects of the ezetimibe-
statin combination therapy can vary according to the pa-
tient sample (e.g. statin naïve versus statin pretreated pa-
tients; acute coronary syndrome versus chronic coronary
disease), and time of assessment of outcome. In a
subanalysis of the PRECISE-IVUS trial, the IVUS end-
points were compared according to the presence or ab-
sence of statin pretreatment [42]. The atorvastatin/
ezetimibe combination showed a significant stronger re-
duction in atheroma volume, compared with atorvastatin
alone, in patients with statin pretreatment. Compensa-
tory increase in cholesterol absorption observed in
statin-treated patients might attenuate the inhibitory ef-
fects of statins on coronary plaque progression.
The results of this meta-analysis showed that with the
lowest LDL-C levels achieved with dual lipid lowering ther-
apy, a greater reduction in plaque volume was observed.
These results suggested that the decrease in LDL-C itself
would be more relevant than the mechanism that generates
it. In that sense, a recent subanalysis of the PRECISE-IVUS
study conducted in patients with acute coronary syndrome
concluded that the regression of coronary atherosclerotic
plaque was associated more with the decrease in LDL-C
than with the established lipid-lowering therapy (high-in-
tensity statins or combined therapy) [43].
The called “LDL hypothesis” assumes that reducing
LDL-C levels, regardless of the means, should pro-
duce a corresponding reduction in cardiovascular
events. An alternative theory, referred as “statin hy-
pothesis”, proposes that statins have a unique efficacy
in atherosclerotic vascular disease that is not shared
by other lipid-modifying agents. Considerable evi-
dence supports the LDL hypothesis, including several
epidemiologic studies and clinical trials of both statins
and non-statin lipid-modifying agents. The Choles-
terol Treatment Trialists’ (CTT) meta-analysis, that
included randomized trials of statins, found that, on
average, a reduction of 1 mmol per liter in LDL-C
levels yields a consistent 23% reduction in the risk of
major coronary events over 5 years [6]. Similarly, in
the IMPROVE-IT and the FOURIER studies the ex-
tent of benefit afforded by the statin-ezetimibe or
statin-evolocumab combination respectively, was con-
sistent with that seen in the CTT meta-analysis, with
Fig. 7 Sensitivity analysis. After replicating the results of the meta-analysis, excluding in each step one of the studies included in the review, the
results obtained are similar
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a similar reduction in cardiovascular events according
to the degree of LDL-C lowering [12, 29].
The non-HDL-C comprises cholesterol carried by all
potentially atherogenic particles, is simpler, more con-
venient and more predictive than LDL-C [44]. The
present study also evaluated the impact of this lipid
marker on atheroma regression, showing similar findings
to the C-LDL analysis.
The process of plaque regression by aggressive LDL-C
lowering therapy could also stabilize the unstable plaque
and reverse the positive remodeling of the vessel wall [45].
As combination therapy with a statin and either ezetimibe
or PCSK9 inhibitors lowers LDL-C levels beyond that
achieved with statin monotherapy, dual lipid-lowering
treatment strategy may have additional protective cardio-
vascular effects [46]. The findings of this meta-analysis
align with these concepts. At present, dual therapy is rec-
ommended to be administered in patients with high or
very high cardiovascular risk who, despite maximum toler-
ated dose of statins, do not reach the recommended lipid
targets. Both ezetimibe and PCSK9 inhibitors are usually
well tolerated with few adverse effects. Continued therapy
should be sustained in such cases.
Limitations
This meta-analysis presents several limitations. First, they are
related with clinical heterogeneity (popular characteristics,
different schemes of lipid-lowering therapy, different follow-
up)and the number of patients included in most of the stud-
ies was low. In fact, the pathophysiological mechanisms in-
volved in acute coronary syndrome are not exactly the same
as in chronic coronary heart disease. However, the statistical
heterogeneity was low and the results were robust when per-
forming the sensitivity analysis, including when the sensitivity
analysis was done only with randomized clinical trials. Sec-
ond, the analysis included only trial-level data without having
the individual data. Third, the meta-regression analysis was
performed with 8 studies, when some authors suggest doing
it with 10 or more. We consider that the number of studies
evaluated approached the suggested number, being also the
total of the available evidence at present. Likewise, meta-
regression in our study is a complement to the main result
that is meta-analysis. Fourth, this study was not designed to
assess the cost effectiveness of non-statin therapy. New stud-
ies in this area should be developed to answer this question.
Finally, we did not perform the analysis with another primary
endpoint, such as the percentage of atheroma volume
(PAV), because these data was not informed in all the ori-
ginal publications.
Conclusion
This data suggest the addition of ezetimibe or PCSK9 in-
hibitors to statin therapy results in significantly in-
creased regression of TAV. When the LDL-C and non-
HDL-C levels reached were lower, the observed effect on
atherosclerosis regression was also greater. The process
of plaque regression by aggressive LDL-C and non-
HDL-C lowering therapy with non-statin drugs can
occur. The decrease in LDL-C and non-HDL-C by
themselves would be more relevant than the mechanism
that generate it and would explain why using these drugs
has an additional protective cardiovascular effect. Future
lipid lowering drugs should also demonstrate their im-
pact on the regression of atherosclerosis.
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